Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig ® ]) in the treatment of patients with primary immunodeficiencies.

Authors :: Kobayashi RH
Gupta S
Melamed I
Mandujano JF
Kobayashi AL
Ritchie B
Geng B
Atkinson TP
Rehman S
Turpel-Kantor E
Litzman J
Source :: Frontiers in immunology [Front Immunol] 2022 Dec 20; Vol. 13, pp. 1110388. Date of Electronic Publication: 2022 Dec 20 (Print Publication: 2022).
Publication Year :: 2022
Abstract: [This corrects the article DOI: 10.3389/fimmu.2019.00040.].<br /> (Copyright © 2022 Kobayashi, Gupta, Melamed, Mandujano, Kobayashi, Ritchie, Geng, Atkinson, Rehman, Turpel-Kantor and Litzman.)

Full Text Access

Tools